\
&
Contact us
\
&
Contact us
Published on | 2 years ago
Programmes Agro-Food, EnvironmentThe first joint call of the Sustainable Blue Economy Partnership (SBEP) was launched on 13 February 2023.
The call entitled “The way forward: a thriving sustainable blue economy for a brighter future” aims to support transnational research and innovation projects (for the duration of 36 months) addressing one of the five priorities specified in the call text and annexes available on the partnership (website: https://bluepartnership.eu/#call)
See also RTD’s website: “European Commission joins forces with 23 countries through the Sustainable Blue Economy Partnership's first joint call launch” and Cascade funding call SBEP in European Funding and tender opportunities.
The closing date for the submission of pre-proposals is set on 14 April 2023 (15h CET).
The activities of this partnership can be followed on:
The website: home | Bluepartnership
Social media:
For any questions, please contact: sbep.call-secretariat@agencerecherche.fr
Source: Funding and Tender Portal
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
AI Continent Deployment: Best use of technologies
The European Commission has published the recording and presentations from its 18 December 2025 info session on the call topics Data Space for Manufacturing (DIGITAL-2026-DSM-AI-09-DS-MANUFACTUR-STEP) and European Digital Media Observatory hubs (DIGITAL-2026-BESTUSE-TECH-EDMO-09-HUBS). The slides and recording are available on ... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
